Climb Bio, Inc.
CLYM
$1.21
-$0.02-1.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 14.92% | 1.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 110.96% | 29.99% | |||
| Operating Income | -110.96% | -29.99% | |||
| Income Before Tax | -146.92% | 5.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -146.92% | 5.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -146.92% | 5.39% | |||
| EBIT | -110.96% | -29.99% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -136.92% | 2.03% | |||
| Normalized Basic EPS | -124.27% | -71.04% | |||
| EPS Diluted | -136.92% | 2.03% | |||
| Normalized Diluted EPS | -124.27% | -71.04% | |||
| Average Basic Shares Outstanding | 4.21% | -3.40% | |||
| Average Diluted Shares Outstanding | 4.21% | -3.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||